Reuters logo
BRIEF-Fennec announces launch of European named patient programme for sodium thiosulfate for pediatric patients with standard risk hepatoblastoma
May 30, 2017 / 11:10 AM / 4 months ago

BRIEF-Fennec announces launch of European named patient programme for sodium thiosulfate for pediatric patients with standard risk hepatoblastoma

May 30 (Reuters) - Fennec Pharmaceuticals Inc

* Fennec announces launch of European named patient programme for sodium thiosulfate for pediatric patients with standard risk hepatoblastoma

* Says Fennec will make STS available for pediatric patients with standard risk hepatoblastoma

* Says pending favorable siopel 6 results, Fennec intends to file NDA/MAA submissions for STS

* Says siopel 6 initial results will be available in Q4 of 2017

* Fennec Pharmaceuticals says Fennec’s NPP is intended to make STS available to patients before commercial availability in certain countries Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below